Study #2020-0755
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination with BMS-986207 (anti-TIGIT antibody) and Nivolumab in Subjects with Advanced Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
COM701 in combination with BMS-986207 and nivolumab.
Description
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
Study phase:
Physician name:
Ecaterina Ileana Dumbrava
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-338-0349
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.